Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
A congressional committee, led by Health Subcommittee Chairman Buddy Carter, is set to hold a hearing focused on the Food and Drug Administration's (FDA) regulation of over-the-counter (OTC) medications. The hearing, scheduled for Wednesday, aims to address concerns regarding the FDA's failure to approve certain products and enforce regulations, which has reportedly led to an increase in illicit and counterfeit items in the market. Chairman Comer emphasized the importance of restoring trust in the FDA and ensuring that Americans have access to safe and reliable OTC medications. Additionally, the Over-the-Counter Monograph Drug User Fee Program, which has facilitated the introduction of over 100,000 safe and affordable medicines, is also a key topic of discussion, with calls for its reauthorization to promote innovation in healthcare and expand options for consumers.
This week, Health Subcommittee Chairman @RepBuddyCarter led a hearing examining the FDA’s regulation of over-the-counter drugs. @HouseCommerce is committed to increasing consumer access and choice to safe, effective medications by reauthorizing OMUFA. https://t.co/uppqQVeTBW
NEW: A congressional committee will take testimony from @HempRoundtable at a hearing on how the FDA "failed to approve products and take necessary enforcement actions resulting in a flood of illicit and counterfeit products" on Wednesday. https://t.co/5V6ZnTrAAs
Now, more than ever, Americans need innovation in health care. The Over-the-Counter Monograph Drug User Fee Program brings 100,000+ safe, affordable medicines to market. Reauthorizing this program will drive more medical breakthroughs and expand options for all Americans. https://t.co/fpccD7R34X
